VEGF genetic polymorphisms affect the responsiveness to sildenafil in clinical and postoperative erectile dysfunction

Pharmacogenomics Journal

Volumn 13, Issue 5, 2013, Pages 437-442

  Lacchini, R ^a   Muniz, J J ^b   Nobre, Y T D A ^a   Cologna, A J ^a   Martins, A C P ^a   Tanus Santos, J E ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

erectile dysfunction; polymorphisms; prostatectomy; sildenafil; VEGF

Indexed keywords

SILDENAFIL; VASCULOTROPIN;

ADULT; ARTICLE; ERECTILE DYSFUNCTION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HAPLOTYPE; HUMAN; INTERNATIONAL INDEX OF ERECTILE FUNCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROMOTER REGION; PROSTATECTOMY; RISK ASSESSMENT; TREATMENT RESPONSE; VEGF GENE;

ERECTILE DYSFUNCTION; HAPLOTYPES; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; POLYMORPHISM, GENETIC; PROMOTER REGIONS, GENETIC; PURINES; SULFONES; UROLOGICAL AGENTS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84884590991     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2012.39     Document Type: Article

References (51)

1. McVary KT. Clinical practice. Erectile dysfunction. N Engl J Med 2007; 357: 2472-2481.
2. Solomon H, Man JW, Jackson G. Erectile dysfunction and the cardiovascular patient: endothelial dysfunction is the common denominator. Heart 2003; 89: 251-253.
3. Inman BA, Sauver JL, Jacobson DJ, McGree ME, Nehra A, Lieber MM et al. A population-based, longitudinal study of erectile dysfunction and future coronary artery disease. Mayo Clin Proc 2009; 84: 108-113.
4. Bocchio M, Scarpelli P, Necozione S, Pelliccione F, Mhialca R, Spartera C et al. Intima-media thickening of common carotid arteries is a risk factor for severe erectile dysfunction in men with vascular risk factors but no clinical evidence of atherosclerosis. J Urol 2005; 173: 526-529.
5. Kloner R. Erectile dysfunction and hypertension. Int J Impot Res 2007; 19: 296-302.
6. Hidalgo-Tamola J, Chitaley K. Review type 2 diabetes mellitus and erectile dysfunction. J Sex Med 2009; 6: 916-926.
7. Lin CS, Lue TF. Growth factor therapy and neuronal nitric oxide synthase. Int J Impot Res 2004; 16(Suppl 1): S38-S39.
8. Marien T, Sankin A, Lepor H. Factors predicting preservation of erectile function in men undergoing open radical retropubic prostatectomy. J Urol 2009; 181: 1817-1822.
9. Awad A, Alsaid B, Bessede T, Droupy S, Benoit G. Evolution in the concept of erection anatomy. Surg Radiol Anat 2011; 33: 301-312.
10. McCullough AR, Hellstrom WG, Wang R, Lepor H, Wagner KR, Engel JD. Recovery of erectile function after nerve sparing radical prostatectomy and penile rehabilitation with nightly intraurethral alprostadil versus sildenafil citrate. J Urol 2010; 183: 2451-2456.
11. McMahon CN, Smith CJ, Shabsigh R. Treating erectile dysfunction when PDE5 inhibitors fail. Br Med J 2006; 332: 589-592.
12. Hood JD, Meininger CJ, Ziche M, Granger HJ. VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells. Am J Physiol 1998; 274: H1054-H1058.
13. van der Zee R, Murohara T, Luo Z, Zollmann F, Passeri J, Lekutat C et al. Vascular endothelial growth factor/vascular permeability factor augments nitric oxide release from quiescent rabbit and human vascular endothelium. Circulation 1997; 95: 1030-1037.
14. Lin CS, Ho HC, Chen KC, Lin G, Nunes L, Lue TF. Intracavernosal injection of vascular endothelial growth factor induces nitric oxide synthase isoforms. BJU Int 2002; 89: 955-960.
15. Shen BQ, Lee DY, Zioncheck TF. Vascular endothelial growth factor governs endothelial nitric-oxide synthase expression via a KDR/Flk-1 receptor and a protein kinase C signaling pathway. J Biol Chem 1999; 274: 33057-33063.
16. Musicki B, Kramer MF, Becker RE, Burnett AL. Inactivation of phosphorylated endothelial nitric oxide synthase (Ser-1177) by O-GlcNAc in diabetes-associated erectile dysfunction. Proc Natl Acad Sci USA 2005; 102: 11870-11875.
17. Musicki B, Kramer MF, Becker RE, Burnett AL. Age-related changes in phosphorylation of endothelial nitric oxide synthase in the rat penis. J Sex Med 2005; 2: 347-355; discussion 355-347.
18. Namba T, Koike H, Murakami K, Aoki M, Makino H, Hashiya N et al. Angiogenesis induced by endothelial nitric oxide synthase gene through vascular endothelial growth factor expression in a rat hindlimb ischemia model. Circulation 2003; 108: 2250-2257.
19. Zhang R, Wang L, Zhang L, Chen J, Zhu Z, Zhang Z et al. Nitric oxide enhances angiogenesis via the synthesis of vascular endothelial growth factor and cGMP after stroke in the rat. Circ Res 2003; 92: 308-313.
20. Komori K, Tsujimura A, Takao T, Matsuoka Y, Miyagawa Y, Takada S et al. Nitric oxide synthesis leads to vascular endothelial growth factor synthesis via the NO/ cyclic guanosine 30,50-monophosphate (cGMP) pathway in human corpus cavernosal smooth muscle cells. J Sex Med 2008; 5: 1623-1635.
21. Rogers RS, Graziottin TM, Lin CS, Kan YW, Lue TF. Intracavernosal vascular endothelial growth factor (VEGF) injection and adeno-associated virus-mediated VEGF gene therapy prevent and reverse venogenic erectile dysfunction in rats. Int J Impot Res 2003; 15: 26-37.
22. Lee MC, El-Sakka AI, Graziottin TM, Ho HC, Lin CS, Lue TF. The effect of vascular endothelial growth factor on a rat model of traumatic arteriogenic erectile dysfunction. J Urol 2002; 167: 761-767.
23. Gholami SS, Rogers R, Chang J, Ho HC, Grazziottin T, Lin CS et al. The effect of vascular endothelial growth factor and adeno-associated virus mediated brain derived neurotrophic factor on neurogenic and vasculogenic erectile dysfunction induced by hyperlipidemia. J Urol 2003; 169: 1577-1581.
24. Sondell M, Lundborg G, Kanje M. Vascular endothelial growth factor has neurotrophic activity and stimulates axonal outgrowth, enhancing cell survival and Schwann cell proliferation in the peripheral nervous system. J Neurosci 1999; 19: 5731-5740.
25. Jin KL, Mao XO, Greenberg DA. Vascular endothelial growth factor: direct neuroprotective effect in in vitro ischemia. Proc Natl Acad Sci USA 2000; 97: 10242-10247.
26. Henry GD, Byrne R, Hunyh TT, Abraham V, Annex BH, Hagen PO et al. Intracavernosal injections of vascular endothelial growth factor protects endothelial dependent corpora cavernosal smooth muscle relaxation in the hypercholesterolemic rabbit: a preliminary study. Int J Impot Res 2000; 12: 334-339.
27. Byrne RR, Henry GD, Rao DS, Huynh TT, Pippen AM, Annex BH et al. Vascular endothelial growth factor restores corporeal smooth muscle function in vitro. J Urol 2001; 165: 1310-1315.
28. Chen KC, Minor TX, Rahman NU, Ho HC, Nunes L, Lue TF. The additive erectile recovery effect of brain-derived neurotrophic factor combined with vascular endothelial growth factor in a rat model of neurogenic impotence. BJU Int 2005; 95: 1077-1080.
29. Park K, Ahn KY, Kim MK, Lee SE, Kang TW, Ryu SB. Intracavernosal injection of vascular endothelial growth factor improves erectile function in aged rats. Eur Urol 2004; 46: 403-407.
30. Vidavalur R, Penumathsa SV, Zhan L, Thirunavukkarasu M, Maulik N. Sildenafil induces angiogenic response in human coronary arteriolar endothelial cells through the expression of thioredoxin, hemeoxygenase and vascular endothelial growth factor. Vascul Pharmacol 2006; 45: 91-95.
31. Sommer F, Klotz T, Engelmann U. Improved spontaneous erectile function in men with mild-to-moderate arteriogenic erectile dysfunction treated with a nightly dose of sildenafil for one year: a randomized trial. Asian J Androl 2007; 9: 134-141.
32. Vardi Y, Appel B, Ofer Y, Greunwald I, Dayan L, Jacob G. Effect of chronic sildenafil treatment on penile endothelial function: a randomized, double-blind, placebo controlled study. J Urol 2009; 182: 2850-2855.
33. Lambrechts D, Storkebaum E, Morimoto M, Del-Favero J, Desmet F, Marklund SL et al. VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat Genet 2003; 34: 383-394.
34. Shahbazi M, Fryer AA, Pravica V, Brogan IJ, Ramsay HM, Hutchinson IV et al. Vascular endothelial growth factor gene polymorphisms are associated with acute renal allograft rejection. J Am Soc Nephrol 2002; 13: 260-264.
35. Awata T, Inoue K, Kurihara S, Ohkubo T, Watanabe M, Inukai K et al. A common polymorphism in the 5'-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes. Diabetes 2002; 51: 1635-1639.
36. Churchill AJ, Carter JG, Ramsden C, Turner SJ, Yeung A, Brenchley PE et al. VEGF polymorphisms are associated with severity of diabetic retinopathy. Invest Ophthalmol Vis Sci 2008; 49: 3611-3616.
37. Goncalves FM, Martins-Oliveira A, Speciali JG, Izidoro-Toledo TC, Luizon MR, Dach F et al. Vascular endothelial growth factor genetic polymorphisms and haplotypes in women with migraine. DNA Cell Biol 2010; 29: 357-362.
38. Sandrim VC, Palei AC, Cavalli RC, Araujo FM, Ramos ES, Duarte G et al. Vascular endothelial growth factor genotypes and haplotypes are associated with pre-eclampsia but not with gestational hypertension. Mol Hum Reprod 2009; 15: 115-120.
39. Howell WM, Ali S, Rose-Zerilli MJ, Ye S. VEGF polymorphisms and severity of atherosclerosis. J Med Genet 2005; 42: 485-490.
40. Biselli PM, Guerzoni AR, de Godoy MF, Pavarino-Bertelli EC, Goloni-Bertollo EM. Vascular endothelial growth factor genetic variability and coronary artery disease in Brazilian population. Heart Vessels 2008; 23: 371-375.
41. Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997; 49: 822-830.
42. Burchardt M, Burchardt T, Chen MW, Shabsigh A, de la Taille A, Buttyan R et al. Expression of messenger ribonucleic acid splice variants for vascular endothelial growth factor in the penis of adult rats and humans. Biol Reprod 1999; 60: 398-404.
43. Belo VA, Souza-Costa DC, Luizon MR, Izidoro-Toledo TC, Lanna CM, Pinheiro LC et al. Vascular endothelial growth factor haplotypes associated with childhood obesity. DNA Cell Biol 2011; 30: 709-714.
44. Demacq C, Vasconcellos VB, Izidoro-Toledo TC, da Silva Silveira V, Canalle R, Queiroz RG et al. Vascular endothelial growth factor (VEGF) and endothelial nitric oxide synthase (NOS3) polymorphisms are associated with high relapse risk in childhood acute lymphoblastic leukemia (ALL). Clin Chim Acta 2010; 411: 1335-1340.
45. Muniz JJ, Lacchini R, Rinaldi TO, Nobre YT, Cologna AJ, Martins AC et al. Endothelial nitric oxide synthase genotypes and haplotypes modify the responses to sildenafil in patients with erectile dysfunction. Pharmacogenomics J 2011.
46. Doronzo G, Russo I, Mattiello L, Anfossi G, Bosia A, Trovati M. Insulin activates vascular endothelial growth factor in vascular smooth muscle cells: influence of nitric oxide and of insulin resistance. Eur J Clin Invest 2004; 34: 664-673.
47. Jesmin S, Sakuma I, Salah-Eldin A, Nonomura K, Hattori Y, Kitabatake A. Diminished penile expression of vascular endothelial growth factor and its receptors at the insulin-resistant stage of a type II diabetic rat model: a possible cause for erectile dysfunction in diabetes. J Mol Endocrinol 2003; 31: 401-418.
48. Liu G, Sun X, Dai Y, Zheng F, Wang D, Huang Y et al. Chronic administration of sildenafil modified the impaired VEGF system and improved the erectile function in rats with diabetic erectile dysfunction. J Sex Med 2010; 7: 3868-3878.
49. Pelliccione F, D'Angeli A, Filipponi S, Falone S, Necozione S, Barbonetti A et al. Serum from patients with erectile dysfunction inhibits circulating angiogenic cells from healthy men: relationship with cardiovascular risk, endothelial damage and circulating angiogenic modulators. Int J Androl 2012.
50. Sandrim VC, Luizon MR, Izidoro-Toledo TC, Coelho EB, Moreno Jr H, Tanus-Santos JE. Functional VEGF haplotypes affect the susceptibility to hypertension. J Hum Hypertens 2011.
51. Yamanaka M, Shirai M, Shiina H, Tanaka Y, Enokida H, Tsujimura A et al. Vascular endothelial growth factor restores erectile function through inhibition of apoptosis in diabetic rat penile crura. J Urol 2005; 173: 318-323.